SMS Lifesciences India Ltd

NSE
SMSLIFE •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in SMS Lifesciences India Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
52W Low on Oct 23, 2023
15.2
TTM PE Ratio
Above industry Median
36.4
Price to Book Ratio
Low in industry
0.9
Dividend yield 1yr %
Below industry Median
0.3
TTM PEG Ratio
PEG TTM is negative
-0.5
RSI
RSI is mid-range
53
MFI
MFI Overbought
77.8

SMS Lifesciences India Ltd Key Financials

*All values are in ₹ Cr.

SMS Lifesciences India Ltd shareholding Pattern

Promoter
70.7%
Public
29.3%

SMS Lifesciences India Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
574.10
10Day EMA
574.90
12Day EMA
575.50
20Day EMA
576.70
26Day EMA
576.00
50Day EMA
567.90
100Day EMA
553.70
200Day EMA
552.00
Delivery & Volume
Resistance & Support
582.30
Pivot
Resistance
First Resistance
604.60
Second Resistance
621.30
Third Resistance
643.60
Support
First Support
565.60
Second support
543.30
Third Support
526.60
Relative Strength Index
52.96
Money Flow Index
77.85
MACD
-0.48
MACD Signal
1.31
Average True Range
30.90
Average Directional Index
23.38
Rate of Change (21)
2.90
Rate of Change (125)
17.51

SMS Lifesciences India Ltd Company background

Founded in: 2006
Managing director: T V V S N Murthy
The Company was incorporated originally as Potluri Real Estate Private Limited on 31May, 2006 for undertaking the activities of real estate business and the Company could not commence business activities andthe companys name has been changed to Potluri Packaging Industries Private Limited on 6 November, 2013. The Company could not undertake any such activities, once again the companys name has been changed to SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector. The Company has become a wholly owned subsidiary company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016. Subsequently converted into a Public Company under the Companies Act, 2013 w.e.f. 22 June, 2016.The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates. The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad.The Demerger Scheme sanctioned by the National Company Law Tribunal (NCLT) vide its order dated 1505 2017 received by the Company on 17052017 has been implemented with appointed date as 01st April, 2016 as provided in the Scheme. Accordingly, the Semi Regulated Facilities i.e., Unit I, IV and V along with (i) premises situated at Industrial Estate, Sanath Nagar, Hyderabad (ii) Industrial Development area, Jeedimetla, Hyderabad (iii) Flat No. 417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad and (iv) Vacant Land admeasuring Ac 19.00 situated at Pharma City, Parawada, Vishakapatnam. Along with these assets the company has conferred with the liabilities mentioned in the books of the demerged company as on the appointed date. The Company allotted 30,23,287 equity shares of Rs.10 each to the shareholders of SMS Pharmaceuticals Limited (transferor Company) on 27 June, 2017 in pursuance of demerger scheme.Pursuant to the scheme of arrangement, the equity shares of the Company were listed in the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 17 August 2017.During the FY2018,the Board approved the acquisition of Mahi Drugs Private Limited (Mahi Drugs), a Bulk Drugs manufacturing Company located at Vishakhapatnam, Andhra Pradesh, as a wholly owned (100%) subsidiary of SMS Lifesciences India Limited by entering into a share purchase agreement.During the FY2019, the Company had achieved production of 2040 M.T of APIs and their Intermediaries in comparison with 1729 M.T for the FY 201718. During the year 201819, Mahi Drugs Private Limited became wholly owned subsidiary of the Company with effect from 17 September, 2018.During the year 201920, producation has declined from 1,364 M.T. of APIs and their intermediates in comparison with 2,040 M.T. for the previous year due to the new USFDA guidelines on Ranitidine HCLThe Company has received the prestigious India Pharma Bulk Drugs Company of the year award on 5 March, 2020 at the 5th edition of India Pharma and Medical Device 2020 conference organized by FICCI in collaboration with Ministry of Chemical and fertilizers, Govt. of India.
Read More

SMS Lifesciences India Ltd FAQs

SMS Lifesciences India Ltd shares are currently priced at 587.9 on NSE and 583.45 on BSE as of 2/22/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of SMS Lifesciences India Ltd [SMSLIFE] share was 4.81. The SMS Lifesciences India Ltd [SMSLIFE] share hit a 1-year low of Rs. 472.05 and a 1-year high of Rs. 707.05.

The market cap of SMS Lifesciences India Ltd is Rs. 177.74 Cr. as of 2/22/2024 12:00:00 AM.

The PE ratios of SMS Lifesciences India Ltd is 20.23 as of 2/22/2024 12:00:00 AM.

The PB ratios of SMS Lifesciences India Ltd is 1.05 as of 2/22/2024 12:00:00 AM

You can easily buy SMS Lifesciences India Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage